The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Treating highly relapsed/refractory CLL
Michael Hallek, MD, of the University Hospital of Cologne, Cologne, Germany, outlines treatment options for relapsed/refractory patients with chronic lymphocytic leukemia and highlights the potential benefit of CAR T-cell therapies for these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
